Sachan Tanya, Gupta Prashant, Suvirya Swastika, Verma Parul, Kumar Kalyan Raj, Banerjee Gopa
Department of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Department of Dermatology, Venerology, and Leprosy, King George's Medical University, Lucknow, Uttar Pradesh, India.
Curr Med Mycol. 2024 Nov 15;10. doi: 10.22034/cmm.2024.345268.1562. eCollection 2024.
Dermatophytosis, a fungal infection targeting keratinized tissue, is caused by dermatophytes, commonly affecting skin, hair, and nails. Prevalent in tropical regions, such as India, its treatment typically utilizes systemic and topical antifungal medications. Despite ample research on oral antifungals, data on the susceptibility of topical treatments, especially in India, where they are prevalent, remains scarce. This study aimed to investigate the antifungal susceptibility of efinaconazole, tavaborole, luliconazole, and sertaconazole against dermatophytes isolated from cases of dermatophytosis.
Samples of all the clinically diagnosed cases of dermatophytosis were subjected to microscopy and culture. All 204 dermatophytes, namely (n=90), (n=69), (n=44), and (n=1) were subjected to antifungal susceptibility testing for efinaconazole, tavaborole, sertaconazole, and luliconazole per Clinical Laboratory Standards Institute broth microdilution method (M38-A3).
The minimum inhibitory concentration values for efinaconazole, tavaborole, sertaconazole, and luliconazole were within the ranges of 0.008-0.5, 1-2, 0.128-2, and 0.004-0.008 µg/ml, respectively across all dermatophytes. Epidemiological cutoff values (ECVs) were 0.004 µg/ml for luliconazole and 2 µg/ml for tavaborole for all dermatophytes. Sertaconazole ECVs were 2 µg/ml for and , 0.5 µg/ml for , and 1 µg/ml for . Tavaborole ECVs for , , , and were 0.5, 0.5, 0.25, and 0.016 µg/ml, respectively.
The results from the present study on the performance of newer topical antifungals suggested that they hold significant promise as prospective candidates for advancing the development of new antifungal treatments for dermatophytosis.
皮肤癣菌病是一种针对角化组织的真菌感染，由皮肤癣菌引起，通常影响皮肤、毛发和指甲。在印度等热带地区较为普遍，其治疗通常使用全身性和局部抗真菌药物。尽管对口服抗真菌药物进行了大量研究，但关于局部治疗的敏感性数据仍然稀缺，尤其是在局部治疗普遍存在的印度。本研究旨在调查艾氟康唑、他氟硼酸盐、卢立康唑和舍他康唑对从皮肤癣菌病病例中分离出的皮肤癣菌的抗真菌敏感性。
对所有临床诊断为皮肤癣菌病的病例样本进行显微镜检查和培养。根据临床实验室标准协会肉汤微量稀释法（M38-A3），对所有204株皮肤癣菌，即红色毛癣菌（n = 90）、须癣毛癣菌（n = 69）、疣状毛癣菌（n = 44）和絮状表皮癣菌（n = 1）进行艾氟康唑、他氟硼酸盐、舍他康唑和卢立康唑的抗真菌敏感性测试。
在所有皮肤癣菌中，艾氟康唑、他氟硼酸盐、舍他康唑和卢立康唑的最低抑菌浓度值分别在0.008 - 0.5、1 - 2、0.128 - 2和0.004 - 0.008 µg/ml范围内。所有皮肤癣菌中，卢立康唑的流行病学截断值（ECV）为0.004 µg/ml，他氟硼酸盐为2 µg/ml。舍他康唑对红色毛癣菌和须癣毛癣菌的ECV为2 µg/ml，对疣状毛癣菌为0.5 µg/ml，对絮状表皮癣菌为1 µg/ml。他氟硼酸盐对红色毛癣菌、须癣毛癣菌、疣状毛癣菌和絮状表皮癣菌的ECV分别为0.5、0.5、0.25和0.016 µg/ml。
本研究关于新型局部抗真菌药物性能的结果表明，它们作为推进皮肤癣菌病新抗真菌治疗药物开发的潜在候选药物具有很大的前景。
